Associated Papers
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Stetka J et al.
Blood, 2023
Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology.
Chia YC et al.
Diagnostics (basel, Switzerland), 2023
A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia.
Hao Z et al.
Frontiers in Oncology, 2023
The prevalence of JAK2 exon12 mutations in Vietnamese patients with JAK2 V617F-negative polycythemia vera: frequent or rare?
Nguyen NT et al.
Human Heredity, 2022
[Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera].
Liu D et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2022
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A et al.
Life (basel, Switzerland), 2021
Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies.
Sidhu I et al.
Cells, 2021
Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
Stuckey R et al.
International Journal of Molecular Sciences, 2021
A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms.
Guijarro-Hernández A et al.
Cancers, 2021
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.
Pastore F et al.
Blood Advances, 2020
Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
Fan J et al.
Journal of Gastroenterology and Hepatology, 2020
JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M et al.
Annals of Hematology, 2020
Diagnosis of exon 12-positive polycythemia vera rescued by NGS.
Geay A et al.
Clinical Case Reports, 2020
Recent insights regarding the molecular basis of myeloproliferative neoplasms.
Jang MA et al.
The Korean Journal of Internal Medicine, 2020
Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations.
Tafesh L et al.
Journal of Pediatric Hematology/oncology, 2019
Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approaches.
Ochoa S et al.
Human Mutation, 2019
Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics.
Lang T et al.
The Journal of International Medical Research, 2018
Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T et al.
Genetic Testing and Molecular Biomarkers, 2018
HIF2A germline-mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma.
Liu Q et al.
Cancer Biology & Therapy, 2017
Detection Mutations of JAK2 exon 12 in Patients with JAK2 (V617F)-negative Myeloproliferative Disorders.
Makani SZ et al.
The Gulf Journal of Oncology, 2017
Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S et al.
British Journal of Haematology, 2017
A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q et al.
Endocrine Pathology, 2017
JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.
Grisouard J et al.
Blood, 2016
High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance.
Park CH et al.
Journal of Clinical Pathology, 2016
Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
Leszczynska A et al.
Acta Haematologica, 2016
Molecular diagnostics of myeloproliferative neoplasms.
Langabeer SE et al.
European Journal of Haematology, 2015
The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y et al.
American Journal of Clinical Pathology, 2015
Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis: an observational study with a systematic review of the literature.
Qi X et al.
European Journal of Gastroenterology & Hepatology, 2015
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Wu Z et al.
Journal of Hematology & Oncology, 2014
JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.
Wang H et al.
Journal of Gastroenterology and Hepatology, 2014
JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.
Edahiro Y et al.
International Journal of Hematology, 2014
Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).
Bento C et al.
European Journal of Haematology, 2013
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
Bench AJ et al.
British Journal of Haematology, 2013
Methods for detecting mutations in the human JAK2 gene.
Bench AJ et al.
Methods in Molecular Biology (clifton, N.j.), 2013
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
Godfrey AL et al.
Blood, 2012
[JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms].
Wang JY et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2012
JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis.
Xia J et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2012
The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory.
Bench AJ
International Journal of Laboratory Hematology, 2012
A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.
Kjær L et al.
Plos One, 2012
The JAK2 exon 12 mutations: a comprehensive review.
Scott LM
American Journal of Hematology, 2011
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F et al.
Oncotarget, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F et al.
Blood, 2011
Genetics of the myeloproliferative neoplasms.
Abdel-Wahab O
Current Opinion in Hematology, 2011
Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
Toyama K et al.
Internal Medicine (tokyo, Japan), 2011
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.
Jatiani SS et al.
Genes & Cancer, 2010
The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
Zhang SJ et al.
International Journal of Laboratory Hematology, 2010
High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera.
Yeh YM et al.
American Journal of Clinical Pathology, 2010